Increasing the radioiodine dose does not improve cure rates in severe graves' hyperthyroidism: a clinical trial with historical control

Jose Miguel Dora, Walter Escouto Machado, Vânia A Andrade, Rafael Selbach Scheffel, Ana Luiza Maia, Jose Miguel Dora, Walter Escouto Machado, Vânia A Andrade, Rafael Selbach Scheffel, Ana Luiza Maia

Abstract

Objective. It is generally accepted that higher doses of radioiodine ((131)I) improve cure rates in Graves' disease (GD). In this trial we sought to evaluate whether very high (131)I doses increase the efficacy of treatment in severe GD. Design. Clinical trial with historical control. Patients with GD and a goiter ≥48 mL were eligible for the study. The patients in the contemporaneous intervention cohort were treated with 250 μ Ci of (131)I/mL thyroid tissue, corrected by 24-RAIU values (Group 1; n = 15). A subgroup of patients with GD and a goiter ≥48 mL who were treated with 200 μ Ci of (131)I/mL/24-RAIU in a previously published randomized controlled trial served as a historical control group (Group 2; n = 15). The primary outcome evaluated was the one-year cure rate. Results. There were no significant baseline differences regarding age, gender, body mass index, smoking status, pretreatment with methimazole, thyroid volume, or thyroid hormone levels of the two treatment groups. The cumulative 12-month cure rate for the patients in Group 1 was 66.6%, a figure similar to the 12-month cure rate observed in Group 2 (60.0%; P = 0.99). Conclusions. Our results suggest that increasing the (131)I dose does not improve cure rates in severe GD. This trial is registered with ClinicalTrials.gov NCT01039818.

Figures

Figure 1
Figure 1
Kaplan-Meier curves indicating the responses of the two study groups to a single dose of 131I. The time to hyperthyroidism control was assessed by the Breslow test (P = 0.40).

References

    1. Ross DS. Radioiodine therapy for hyperthyroidism. The New England Journal of Medicine. 2011;364(6):542–550.
    1. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves’ disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid. 1999;9(12):1181–1188.
    1. Jarlov AE, Hegedust L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clinical Endocrinology. 1995;43(3):325–329.
    1. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. Journal of Clinical Endocrinology and Metabolism. 2001;86(8):3488–3493.
    1. Alexander EK, Larsen PR. High dose 131I therapy for the treatment of hyperthyroidism caused by Graves’ disease. Journal of Clinical Endocrinology and Metabolism. 2002;87(3):1073–1077.
    1. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in graves’ hyperthyroidism. Journal of Clinical Endocrinology and Metabolism. 2003;88(3):978–983.
    1. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646.
    1. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. British Medical Journal. 2007;334(7592):514–517.
    1. Sztal-Mazer S, Nakatani VY, Bortolini LG, Boguszewski CL, Graf H, de Carvalho GA. Evidence for higher success rates and successful treatment earlier in graves' disease with higher radioactive iodine doses. Thyroid. 2012;22:991–995.
    1. Hernandez-Jimenez S, Pachon-Burgos A, Aguilar-Salinas CA, et al. Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage. Archives of Medical Research. 2007;38:185–189.
    1. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111(4):745–749.
    1. Schiavo M, Bagnara MC, Calamia I, et al. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves’ disease: need to retarget the radiation committed dose to the thyroid. Journal of Endocrinological Investigation. 2011;34(3):201–205.
    1. Esfahani AF, Kakhki VRD, Fallahi B, et al. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves’ disease resistant to antithyroid drugs. Hellenic Journal of Nuclear Medicine. 2005;8(3):158–161.
    1. Martin NM, Patel M, Nijher GM, Misra S, Murphy E, Meeran K. Adjuvant lithium improves the efficacy of radioactive iodine treatment in graves' and toxic nodular disease. Clinical Endocrinology. 2012;77:621–627.
    1. Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12(5):399–405.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe